Physician profile
Gregory B Floyd
NPI 1326066895
$8,804.90
in general payments reported to CMS, 2019-2025
46 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $1,231 · 2021: $1,895 · 2022: $1,159 · 2023: $1,194 · 2024: $1,174 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,411 · Entertainment: $13.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.68 |
| Entertainment | $13.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,296.69 | 2019-2024 | |
| Novo Nordisk INC | $957.19 | 2019-2025 | Wegovy, Rybelsus |
| Astellas Pharma US INC | $687.81 | 2019-2022 | |
| Pfizer INC. | $647.37 | 2019-2025 | |
| Esperion Therapeutics, INC. | $585.79 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $572.00 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $539.09 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $502.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $450.56 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $298.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.92 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $190.28 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $143.77 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.96 | 2019-2024 | Xifaxan |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.